PAPER NOW AVAILABLE: Health Law Workshop: Ameet Sarpatwari image

November 12, 2018 5:00 PM
Health Law Workshops
2018-2019
Hauser Hall, Room 104
Harvard Law School, 1575 Massachusetts Ave., Cambridge, MA

Presentation: "The U.S. Follow-On Biologic Market"

This paper is not available for download. To request a copy in preparation for the workshop, please contact Jennifer Minnich at jminnich@law.harvard.edu.

Ameet Sarpatwari is an Instructor in Medicine at Harvard Medical School, an Associate Epidemiologist at Brigham and Women’s Hospital, and Assistant Director of the Program On Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes. Among other projects, he is currently examining the public health impact of risk evaluation and mitigation strategies, the comparative safety and effectiveness of authorized and non-authorized generics, and the effect of variation in state drug product selection laws on generic drug prescribing.

Dr. Sarpatwari completed his undergraduate studies at the University of Virginia, where he was a Jefferson Scholar. He studied epidemiology at the University of Cambridge, where his doctoral work centered on uncovering disease progression, treatment effectiveness, and co-morbid burden among adults patients with primary immune thrombocytopenia. He subsequently studied law at the University of Maryland as a John L. Thomas Leadership Scholar.

Dr. Sarpatwari is currently the Principal Investigator on a Greenwall Foundation Making a Difference in Real-World Bioethics Dilemmas grant and a Faculty Affiliate with the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Behavioral Insights Group at the Harvard Kennedy School. He teaches an annual course on Public Health Law at the Harvard T.H. Chan School of Public Health.

Tags

biotechnology   health care costs   health law policy   pharmaceuticals   public health   regulation